Redx Pharma plc Redx to present two posters at AACR 2019

TIDMREDX

Redx Pharma plc

29 March 2019

REDX PHARMA PLC

("Redx" or "the Company")

Redx Pharma to present two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting

Posters show that RXC004 has the ability to directly target tumour growth and stimulate the host immune response against tumours

Alderley Park, 29 March 2019 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the two abstracts submitted by the Company have been accepted for presentation as posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, taking place between 29 March and 3 April 2019.

Both posters relate to the Company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine (PORCN) inhibitor which targets the Wnt signalling pathway. The posters present preclinical data confirming the potential for RXC004 in modulating the immune system of the tumour microenvironment (poster #506) as well as preclinical data on the direct tumour-targeting effects of RXC004 in genetically-defined models of cancer (poster #3874).

Redx is evaluating RXC004 in an ongoing first-in-man clinical trial. The trial is a modular, multi-arm, multi-part, Phase 1/2a, adaptive design study whose primary objective is to evaluate the safety and tolerability of the drug in patients with advanced malignancies (ClinicalTrials.gov Identifier: NCT03447470).

Richard Armer, Chief Scientific Officer of Redx Pharma plc commented, "We are delighted to be presenting again at this high-profile cancer conference. These poster presentations demonstrate our continued understanding of how RXC004 is able to have both direct and immunomodulatory effects on tumours in various preclinical cancer models. This preclinical data will inform design of future clinical studies to investigate the full potential of this mechanism."

Details of the poster presentations are as follows:

1)

 
 Abstract Title:         Wnt/<BETA>-Catenin pathway inhibitor 
                          RXC004 enhances the immunity 
                          of pre-clinical models of cancer 
 Session Title:          Metabolic Mechanisms That Modulate 
                          the Immune Response to Cancer 
 Date/Time:              March 31, 2019, 1:00 PM - 5:00 
                          PM CST 
 Location:               Poster Section 21 
 Poster Board Number:    5 
 Poster Number:          506 
 

2)

 
 Abstract Title:         Efficacy of the Wnt/Beta-Catenin 
                          pathway inhibitor RXC004 in 
                          genetically-defined models of 
                          cancer 
 Session Title:          Novel Antitumor Agents 2 
 Date/Time:              April 2, 2019, 1:00 PM - 5:00 
                          PM CST 
 Location:               Poster Section 12 
 Poster Board Number:    24 
 Poster Number:          3874 
 

For further information, please contact:

 
Redx Pharma Plc                                T: [phone] 
                                                920 
Lisa Anson, Chief Executive Officer 
Andrew Saunders, Chief Medical Officer 
 
Cantor Fitzgerald Europe (Nominated Advisor &  T: [phone] 
 Joint Broker)                                  7000 
Phil Davies 
 
 
WG Partners LLP (Joint Broker)                 T: [phone] 
                                                9330 
Claes Spång/ Chris Lee/ David Wilson 
 
 
FTI Consulting                                 T: [phone] 
                                                1000 
Simon Conway/Ciara Martin 
 

About Redx Pharma Plc

Redx is a UK-based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAVVLFLKXFLBBF

(END) Dow Jones Newswires

March 29, 2019 03:02 ET (07:02 GMT)